We aim to provide better alternatives to patients around the globe &
We fight daily because we know patients are too.  


Our initial focus is on oral cancer followed by intra-opertaive chemotherapy and HPV caused cancers.

Privo's Phase II clinical study on oral cancer is near completion



Privo is excited to work closely with its collaborators at the FDA, the NCI and the NIDCR.

Privo Technologies has received over $11M in nondilutive funding from these institutions in support of its product development and clinical trial.

Clinical Trials

Privo is currently recruiting subjects for its Phase II clinical trial